Summit Therapeutics (SUMM)

 

SUMM Share PerformanceMore

52 week high262.00 04/10/16
52 week low88.00 16/09/16
52 week change 69.00 (63.40%)
4 week volume368,536 01/06/17

Media for (SUMM)

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Summit Presents Data from Phase 1 Clinical Programme of Ezutromid at the EPNS Congress

Summit Presents Data from Phase 1 Clinical Programme of Ezutromid at the EPNS Congress Summit Therapeutics plc ('Summit', or 'the Company') SUMMIT PRESENTS DATA FROM PHASE 1 CLINICAL PROGRAMME OF EZUTROMID AT THE EUROPEAN PAEDIATRIC NEUROLOGY SOCIETY CONGRESS Oxford, UK, 22 June 2017 - Summit Therapeu...

Four AIM shares for a post-election world

Given UK political uncertainty, former AIM writer of the year Andrew Hore names companies exposed to overseas earnin...

Summit Therapeutics to Participate in JMP Securities Life Sciences Conference

Summit Therapeutics to Participate in JMP Securities Life Sciences Conference Summit Therapeutics plc ("Summit", or the "Company") SUMMIT THERAPEUTICS TO PARTICIPATE IN JMP SECURITIES LIFE SCIENCES CONFERENCE Oxford, UK, 15 June 2017- Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), the drug discovery and development c...

Summit losses fall

Summit Therapeutics has reported a loss for the three months ended 30 April 2017 of 4.8m, compared to a loss of 5.4m for ...

Summit Therapeutics plc : 1st Quarter Results

Summit Therapeutics plc: 1st Quarter Results Summit Therapeutics plc ('Summit', the 'Company' or the 'Group') SUMMIT THERAPEUTICS REPORTS FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED 30 APRIL 2017 AND OPERATIONAL PROGRESS Oxford, UK, 14 June 2017 - Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT), the drug disc...

Summit confirms date of Q1 results announcement

Summit Therapeutics said it will announce its financial results for the first quarter ended 30 April on 14 June. At 2:59pm: (...

Summit Therapeutics plc : Notice of Results

Summit Therapeutics plc: Notice of Results Summit Therapeutics plc ("Summit" or the "Company") SUMMIT THERAPEUTICS TO REPORT FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED 30 APRIL 2017 ON 14 JUNE 2017 Oxford, UK, 13 June 2017 - Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT), the drug discovery and development c...

Summit highlights benefits of ridinilazole at ASM Microbe

Summit Therapeutics has announced that the Company presented new preclinical data on ridinilazole were at ASM Micro...

Fundamental DataMore

EPS-44
Dividend yield0 %

Latest discussion posts More

  • Re: NEW ARTICLE: Four AIM shares for a post-...

    The article referenced on Interactive Investor states that Summit Therapeutics has 2 potential treatments "both well down the road to becoming proven and commercial products". ...
    18-Jun-2017
    pharmaspecialist
  • NEW ARTICLE: Four AIM shares for a post-election world

    "Weakening retail figures and the post-election uncertainty are not a great backdrop for UK-focused companies.The Conservatives have, at the moment, not completed a deal with ...
    16-Jun-2017
    II Editor
  • Final results out

    DMD drug trial update Q1 2018. Cdif drug Phase 3 to start Q1 2018. High cash burn. May get more up front from Sarepta 2017. DYOR
    29-Mar-2017
    bobsson

Users' HoldingsMore

Users who hold Summit Therapeutics also hold..
RANGE RES.20%
LLOYDS GRP.20%
ROYAL BANK SCOT17%
SIRIUS MINERALS15%
TESCO13%

Codes & Symbols

ISINGB00BN40HZ01
SymbolsSUMM, LSE:SUMM, SUMM.L, SUMM:LN, LON:SUMM, XLON:SUMM